Statins in the treatment of lipid metabolism disorders: Regardless of the level of total cholesterol (TC), diabetic patients have a 2 to 4 times higher incidence of coronary heart disease than non-diabetic patients. This is precisely because the structural changes in LDL of diabetic patients induce arterial atherosclerosis more strongly than normal LDL. The American Diabetes Association (ADA) published guidelines for abnormal lipid metabolism and prevention, making it clear that the primary goal of treating dyslipidemia in diabetic patients is to lower LDL-C. The control target for LDL-C is 1.15 mmol/L, with female HDL-C > 1.30 mmol/L. ATP III also pointed out that patients with type 2 diabetes are often associated with atherogenic atherosclerotic dyslipidemia, and lowering LDL-C should be the primary treatment goal. In ATPm, diabetes is considered a CAD risk equivalent disease, so the treatment goal for most patients' LDL-C is ≤ 2.6 mmol/L. Furthermore, when LDL-C ≥ 3.4 mmol/L, most diabetic individuals need to start using medications to reduce LDL-C, while implementing therapeutic lifestyle changes to standardize LDL-C. Based on the results of large-scale clinical trials published from 2002 to 2004, the ATPm Committee of Experts discussed and published a new report proposing that for diabetic patients with existing coronary heart disease, LDL-C should be decreased to below 2.07 mmol/L. If TG ≥ 5.65 mmol/L, fibrates should be used, with the first task being to lower TG to prevent acute pancreatitis. If TG is 2.76 mmol/L, fenofibrate and statins can be safely used long-term together. If TG < 5.65 mmol/L and LDL-C is standardized, non-HDL-C should be regarded as a secondary lipid treatment target, then Beit drugs or sustained-release niacin can be used. When statins are combined with Beit drugs, we should try to select medications with higher safety among Beit drugs, such as preferring fenofibrate over gemfibrozil. During follow-up, besides monitoring ALT, CK, BUN, and Cr, one should also inquire about symptoms like muscle weakness or pain, and if any apparent abnormalities occur, the medication should be promptly discontinued. Whether using statins or fibrates, emphasis should be placed on the safety of the drug and the appropriate dosage. Relying solely on increasing the dose of a drug does not bring additional benefits according to some large-scale studies; blind high-dose strengthening shows minimal further benefit in lipid lowering but increases the risk of adverse reactions. In summary, the primary target of lipid-lowering therapy in diabetic patients is to lower LDL-C to the standard, and statins are currently the most effective drugs for reducing LDL-C, making them the first choice for treating abnormal lipid metabolism in diabetes. Statins currently listed can be used for the treatment of abnormal lipid metabolism in diabetes, and they can reduce cardiovascular events in diabetic patients, providing long-term benefits for patients with abnormal lipid metabolism. Evaluation of Medicinal Products 2009 6 6 227.